NAFDAC stresses need to identify original AstraZeneca vaccine before administration

Advertisements
Advertisements
Advertisements
Advertisements
Advertisements
Advertisements
Advertisements
Advertisements
Advertisements
Advertisements

-SHARE THIS-
The National Agency for Food, Drug Administration and Control (NAFDAC) has stressed the need to identify the original AstraZeneca vaccine before allowing administration, even as it said the original vaccine can be identified by the originality of its label.

Advertisements

According to the agency, the vaccines manufactured by Serum Institute of India PVT Ltd (SIIPL) were accredited by the World Health Organisation (WHO), and were being used in about 170 countries around the world.

Advertisements

Emphasizing this in a statement, Sunday, NAFDAC Director General, Prof. Mojisola Adeyeye, stated that both COVISHIELD manufactured by SIIPL and COVID-19 vaccine Astrazeneca, manufactured by Astrazeneca/Oxford University vaccine, though coming in different trade names, are the same vaccine, and only require informed knowledge to differentiate.

Advertisements


According to Adeyeye, the original Oxford Astrazeneca University (AZOU) vaccine has been contracted to India’s world largest vaccine manufacturer, Serum Institute of India PVT Ltd (SIIPL), to produce in large quantity.

“AZOU gave the license of its vaccine to Serum Institute of India PVT Ltd (SIIPL), to manufacture this vaccine at a commercial scale. SIIPL is the largest vaccine manufacturer in the world and the company got the license by signing the manufacturing agreement.

“SIIPL gave the vaccine the trade name COVISHIELD, it is the result of a cooperation and a technology transfer from AstraZeneca – University of Oxford to SIIPL.

“SIIPL is now the world’s largest vaccine manufacturer by number of doses produced and sold globally. These include more than 1.5 billion doses, which include Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella,” she informed, adding that ChAdOx1 nCoV- 19 corona virus vaccines (Recombinant), COVISHIELD, was granted Emergency Use Listing (EUL) by the World Health Organisation on Feb.15, and that it was one of the listed vaccines under the COVAX Facility.

• Tags: NAFDAC, Prof. Mojisola Adeyeye, AstraZeneca vaccine

Advertisements

Leave a Reply

Your email address will not be published. Required fields are marked *